ArticleStem cell research & therapy2025
LINC01013 reverses bisphosphonate-impaired osteogenic differentiation of JBMMSCs by regulating intracellular translocation of ILF3.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protein Arginine Methyltransferase 6 Regulated Odontogenic Differentiation and Mitochondrial Function of Stem Cells from Apical Papilla Through its Nuclear Localization Sequence via β-catenin Pathway.International dental journal · 2026Article
- Targeting ferroptosis to rescue osteogenic differentiation in BRONJ-affected jawbone mesenchymal stem cells: the role of miR-145-3p and exosome-mediated therapy.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious complication associated with bisphosphonate (BP) therapy. Enhancement of the osteogenic differentiation of human jaw bone marrow mesenchymal stem cells (JBMMSCs) is a key issue in the treatment of BRONJ. In this study, we investigated the role and mechanism of LINC01013 in regulating osteogenic differentiation of JBMMSCs.
methodsOsteogenic differentiation of JBMMSCs was assessed in vitro using alkaline phosphatase (ALP), alizarin red staining (ARS), and western blotting. JBMMSCs transplanted into the backs of nude mice were used to detect JBMMSCs osteogenesis in vivo. Molecular mechanisms involved in JBMMSCs osteogenesis were evaluated using real-time fluorescence quantitative polymerase chain reaction, western blotting, fluorescence in situ hybridization, RNA pull-down, and RNA-seq.
resultsHomeobox C8 (HOXC8) knockdown enhanced ALP activity, ARS, and expression of bone sialoprotein and osteocalcin in JBMMSCs under normal and BP stimulation conditions. HOXC8 negatively regulated LINC01013 expression. LINC01013 enhanced JBMMSCs osteogenic differentiation impaired by BP stimulation. Furthermore, LINC01013 regulated the expression of inflammation-related genes in JBMMSCs under BP conditions. LINC01013 formed a complex with ILF3. Two isoforms of ILF3 (NF90 and NF110) promoted the osteogenic differentiation of JBMMSCs under normal and BP conditions, depending on their nuclear localization. Additionally, NF90, which is located in the nucleus, inhibited the expression of NLR family pyrin domain containing 3 (NLRP3).
conclusionsIn summary, HOXC8 negatively regulates LINC01013 to inhibit osteogenic differentiation of JBMMSCs under BP conditions. We also further clarified that LINC01013 binding to ILF3 affects ILF3 nuclear localization to regulate JBMMSCs osteogenic differentiation and regulates NLRP3/Caspase-1 pathway to affect JBMMSCs function under BP stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.